Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
作者信息
Kersten M J, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin P M, van der Holt B J, Spaargaren M, Pals S T
机构信息
Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
出版信息
Blood Cancer J. 2014 Dec 12;4(12):e266. doi: 10.1038/bcj.2014.87.
Abstract
摘要
相似文献
1
Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
Blood Cancer J. 2014 Dec 12;4(12):e266. doi: 10.1038/bcj.2014.87.
2
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Cancer. 2017 Apr 1;123(7):1166-1173. doi: 10.1002/cncr.30404. Epub 2016 Dec 4.
3
MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):311-318. doi: 10.1097/PAI.0000000000000585.
4
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20.
5
Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Leuk Lymphoma. 2015 Jul;56(7):2141-5. doi: 10.3109/10428194.2014.979413. Epub 2015 Jan 14.
6
Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Am J Surg Pathol. 2020 Apr;44(4):444-455. doi: 10.1097/PAS.0000000000001386.
7
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant and wildtype .
Haematologica. 2017 Jul;102(7):e275-e277. doi: 10.3324/haematol.2016.161893. Epub 2017 Mar 24.
8
High prevalence of and mutations in intravascular large B-cell lymphoma.
Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7.
9
A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88 /CD79B diffuse large B-cell lymphoma.
Cancer Med. 2024 Feb;13(4):e7005. doi: 10.1002/cam4.7005.
10
[Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):258. doi: 10.3760/cma.j.issn.0253-2727.2023.03.015.
引用本文的文献
1
Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.
Br J Haematol. 2025 Jul;207(1):92-100. doi: 10.1111/bjh.20099. Epub 2025 Apr 22.
2
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma.
Exp Hematol Oncol. 2024 Jan 3;13(1):1. doi: 10.1186/s40164-023-00467-2.
3
Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.
Cancers (Basel). 2022 Apr 7;14(8):1857. doi: 10.3390/cancers14081857.
4
mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.
Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.
5
Biology of CNS lymphoma and the potential of novel agents.
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):556-564. doi: 10.1182/asheducation-2017.1.556.
本文引用的文献
1
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20.
2
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.
Blood Cancer J. 2013 Sep 6;3(9):e139. doi: 10.1038/bcj.2013.28.
3
The genetic basis of diffuse large B-cell lymphoma.
Curr Opin Hematol. 2013 Jul;20(4):336-44. doi: 10.1097/MOH.0b013e3283623d7f.
4
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.
5
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
6
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
Clin Cancer Res. 2012 Oct 1;18(19):5203-11. doi: 10.1158/1078-0432.CCR-12-0845. Epub 2012 Jul 26.
7
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.
8
Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.
Acta Neuropathol. 2011 Dec;122(6):791-2. doi: 10.1007/s00401-011-0891-2. Epub 2011 Oct 22.
9
Oncogenically active MYD88 mutations in human lymphoma.
Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.
10
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
J Clin Oncol. 2010 May 10;28(14):2373-80. doi: 10.1200/JCO.2009.26.2493. Epub 2010 Apr 12.
Zotero 插件